Multivariable linear mixed models to predict changes in skin severity according to 9 different measures
| Sequential change of skin severity measures/Contrast in clinician or patient perception of skin change . | Clinician . | Patient . | ||
|---|---|---|---|---|
| Estimate (95% CI) . | P . | Estimate (95% CI) . | P . | |
| NIH response erythema*scale9 | ||||
| Improve vs stable | −10.49 (−14 ∼ −6.97) | < .001 | −5.58 (−9.81 ∼ −1.36) | .01 |
| Worsen vs stable | 6.42 (0.48 ∼ 12.36) | .03 | 6.17 (−2.26 ∼ 14.59) | .15 |
| NIH response movable sclerosis scale9 | ||||
| Improve vs stable | −2.07 (−3.82 ∼ −0.31) | .02 | −0.8 (−2.72 ∼ 1.12) | .41 |
| Worsen vs stable | 1.35 (−1.62 ∼ 4.32) | .37 | −1.36 (−5.18 ∼ 2.47) | .49 |
| NIH response nonmovable sclerosis scale9 | ||||
| Improve vs stable | −0.44 (−1.62 ∼ 0.74) | .47 | 0.05 (−1.2 ∼ 1.31) | .93 |
| Worsen vs stable | 5.13 (3.14 ∼ 7.12) | < .001 | 1.95 (−0.56 ∼ 4.46) | .13 |
| Vienna Total Score15 | ||||
| Improve vs stable | −1.63 (−2.21 ∼ −1.05) | < .001 | −0.55 (−1.24 ∼ 0.13) | .11 |
| Worsen vs stable | 1.8 (0.82 ∼ 2.78) | < .001 | 1.16 (−0.21 ∼ 2.53) | .10 |
| Hopkins sclerotic scale6 | ||||
| Improve vs stable | −0.14 (−0.29 ∼ 0.01) | .07 | −0.09 (−0.26 ∼ 0.07) | .27 |
| Worsen vs stable | 0.4 (0.15 ∼ 0.65) | .002 | 0.26 (−0.08 ∼ 0.59) | .13 |
| Hopkins fascia scale6 | ||||
| Improve vs stable | −0.15 (−0.26 ∼ −0.03) | .01 | −0.1 (−0.22 ∼ 0.02) | .09 |
| Worsen vs stable | 0.09 (−0.1 ∼ 0.27) | .36 | 0.04 (−0.2 ∼ 0.28) | .73 |
| Skin itching | ||||
| Improve vs stable | −0.3 (−0.85 ∼ 0.25) | .28 | −0.53 (−1.06 ∼ −0.01) | .05 |
| Worsen vs stable | 0.81 (−0.11 ∼ 1.73) | .08 | 2.88 (1.82 ∼ 3.94) | < .001 |
| NIH composite 0-3 score8 | ||||
| Improve vs stable | −0.74 (−0.93 ∼ −0.56) | < .001 | −0.36 (−0.58 ∼ −0.14) | .002 |
| Worsen vs stable | 0.78 (0.46 ∼ 1.09) | < .001 | 0.79 (0.35 ∼ 1.24) | < .001 |
| Skin subscale, Lee Symptom Scale16 | ||||
| Improve vs stable | −11.9 (−16.05 ∼ −7.76) | < .001 | −8.75 (−12.7 ∼ −4.79) | < .001 |
| Worsen vs stable | 9.89 (2.84 ∼ 16.93) | .006 | 28.91 (20.64 ∼ 37.18) | < .001 |
| Sequential change of skin severity measures/Contrast in clinician or patient perception of skin change . | Clinician . | Patient . | ||
|---|---|---|---|---|
| Estimate (95% CI) . | P . | Estimate (95% CI) . | P . | |
| NIH response erythema*scale9 | ||||
| Improve vs stable | −10.49 (−14 ∼ −6.97) | < .001 | −5.58 (−9.81 ∼ −1.36) | .01 |
| Worsen vs stable | 6.42 (0.48 ∼ 12.36) | .03 | 6.17 (−2.26 ∼ 14.59) | .15 |
| NIH response movable sclerosis scale9 | ||||
| Improve vs stable | −2.07 (−3.82 ∼ −0.31) | .02 | −0.8 (−2.72 ∼ 1.12) | .41 |
| Worsen vs stable | 1.35 (−1.62 ∼ 4.32) | .37 | −1.36 (−5.18 ∼ 2.47) | .49 |
| NIH response nonmovable sclerosis scale9 | ||||
| Improve vs stable | −0.44 (−1.62 ∼ 0.74) | .47 | 0.05 (−1.2 ∼ 1.31) | .93 |
| Worsen vs stable | 5.13 (3.14 ∼ 7.12) | < .001 | 1.95 (−0.56 ∼ 4.46) | .13 |
| Vienna Total Score15 | ||||
| Improve vs stable | −1.63 (−2.21 ∼ −1.05) | < .001 | −0.55 (−1.24 ∼ 0.13) | .11 |
| Worsen vs stable | 1.8 (0.82 ∼ 2.78) | < .001 | 1.16 (−0.21 ∼ 2.53) | .10 |
| Hopkins sclerotic scale6 | ||||
| Improve vs stable | −0.14 (−0.29 ∼ 0.01) | .07 | −0.09 (−0.26 ∼ 0.07) | .27 |
| Worsen vs stable | 0.4 (0.15 ∼ 0.65) | .002 | 0.26 (−0.08 ∼ 0.59) | .13 |
| Hopkins fascia scale6 | ||||
| Improve vs stable | −0.15 (−0.26 ∼ −0.03) | .01 | −0.1 (−0.22 ∼ 0.02) | .09 |
| Worsen vs stable | 0.09 (−0.1 ∼ 0.27) | .36 | 0.04 (−0.2 ∼ 0.28) | .73 |
| Skin itching | ||||
| Improve vs stable | −0.3 (−0.85 ∼ 0.25) | .28 | −0.53 (−1.06 ∼ −0.01) | .05 |
| Worsen vs stable | 0.81 (−0.11 ∼ 1.73) | .08 | 2.88 (1.82 ∼ 3.94) | < .001 |
| NIH composite 0-3 score8 | ||||
| Improve vs stable | −0.74 (−0.93 ∼ −0.56) | < .001 | −0.36 (−0.58 ∼ −0.14) | .002 |
| Worsen vs stable | 0.78 (0.46 ∼ 1.09) | < .001 | 0.79 (0.35 ∼ 1.24) | < .001 |
| Skin subscale, Lee Symptom Scale16 | ||||
| Improve vs stable | −11.9 (−16.05 ∼ −7.76) | < .001 | −8.75 (−12.7 ∼ −4.79) | < .001 |
| Worsen vs stable | 9.89 (2.84 ∼ 16.93) | .006 | 28.91 (20.64 ∼ 37.18) | < .001 |
The linear mixed models were used to predict clinician or patient-reported change in skin involvement according to sequential changes in skin severity by 9 different measures (P ≤ .01 in bold). Each model includes one sequential change measure as the outcome, one perceived change measure as the covariate of interest, and controls for study site and for factors related to perceived change (Karnofsky performance status, case type, and months from HCT to enrollment).
NIH indicates National Institutes of Health; CI, confidence interval; and HCT, hematopoietic cell transplantation.
Includes any cutaneous manifestations other than sclerosis and fasciitis.